Displaying drugs 15226 - 15250 of 15477 in total
2,6-dibromo-4-phenoxyphenol
Experimental
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole targets the protein genome polyprotein.
Experimental
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Henagliflozin
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Investigational
Chlorproguanil
Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.
Investigational
Clofoctol
Experimental
Tolpropamine
Experimental
Suloctidil
Experimental
Eprozinol
Experimental
Etybenzatropine
Experimental
Tiocarlide
Experimental
Quifenadine
Experimental
Penfluridol
Experimental
AGI-1096
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
Bleximenib
Bleximenib is under investigation in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and NCT05453903 (A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies)
Investigational
Matched Description: … in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and …
KD7040
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Investigational
Matched Description: … The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and …
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and …
Displaying drugs 15226 - 15250 of 15477 in total